E
Metagenomi, Inc. MGX
$2.89 $0.113.96% NASDAQ
Recommendation
Prev Close
$2.89
Volume
273,352
Avg Vol (90D)
701,691
Market Cap
$108.47M
Dividend & Yield
--
52-Week Range
$1.23 - $4.92
P/E (TTM)
--
EPS (TTM)
-$2.35
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Metagenomi (NASDAQ:MGX) Raised to "Hold" at Wall Street Zen
10/25/2025 - MarketBeat
Metagenomi (MGX) Adopts AWS AI Chips to Boost Gene-Editing Innovations
10/22/2025 - GuruFocus
Metagenomi to use Amazon's chips for gene-editing tools
10/22/2025 - SeekingAlpha.com: All News
Metagenomi to use Amazon's chips for gene-editing tools
10/22/2025 - Seeking Alpha - Healthcare
Dropping Nvidia for Amazon's custom chips helped gene therapy startup Metagenomi cut AI bill 56%
10/22/2025 - The Register
H.C. Wainwright Sticks to Their Buy Rating for Metagenomi, Inc. (MGX)
10/22/2025 - TipRanks Financial Blog
Metagenomi taps Amazon's custom chips to develop gene-editing tools
10/22/2025 - Channel NewsAsia - Business News
Metagenomi, Inc. (NASDAQ:MGX) Given Consensus Recommendation of "Moderate Buy" by Analysts
10/21/2025 - MarketBeat
Here's Why Metagenomi (MGX) is a Great Momentum Stock to Buy
10/20/2025 - Zacks Investment Research
Metagenomi's (MGX) Sell (D-) Rating Reaffirmed at Weiss Ratings
10/10/2025 - MarketBeat
Metagenomi Regains Control After Affini-T Agreement Termination
10/1/2025 - TipRanks Financial Blog
VTI's Underlying Holdings Could Mean 10% Gain Potential
9/24/2025 - ETF Channel
Metagenomi, Inc. $MGX Shares Sold by Hhlr Advisors LTD.
9/3/2025 - MarketBeat
Chardan Capital Reduces Earnings Estimates for Metagenomi
8/23/2025 - MarketBeat
Metagenomi's (MGX) "Buy" Rating Reaffirmed at HC Wainwright
8/21/2025 - MarketBeat
Chardan Capital Cuts Metagenomi (NASDAQ:MGX) Price Target to $11.00
8/17/2025 - MarketBeat
Wells Fargo & Company Issues Pessimistic Forecast for Metagenomi (NASDAQ:MGX) Stock Price
8/16/2025 - MarketBeat
Metagenomi price target lowered by $1 at Chardan, here's why
8/15/2025 - The Fly
Metagenomi (NASDAQ:MGX) Price Target Cut to $12.00 by Analysts at Wells Fargo & Company
8/15/2025 - Ticker Report
Metagenomi (NASDAQ:MGX) Releases Earnings Results, Beats Estimates By $0.14 EPS
8/15/2025 - MarketBeat
Metagenomi, Inc. Reports Q2 2025 Financial Results
8/13/2025 - TipRanks Financial Blog
Metagenomi, Inc. (MGX) Gets a Buy from TD Cowen
8/12/2025 - TipRanks Financial Blog
Metagenomi (MGX) Reports Q2 Loss, Tops Revenue Estimates
8/12/2025 - Zacks Investment Research
Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates
8/12/2025 - Zacks Investment Research
Metagenomi GAAP EPS of -$0.54 beats by $0.08, revenue of $8.51M beats by $0.79M
8/12/2025 - SeekingAlpha.com: All News
Income Statement
Total Revenue (TTM)
$33.77M
EBITDA (TTM)
-$86.30M
EBIT (TTM)
-$91.81M
Net Income (TTM)
-$87.12M
Balance Sheet
Total Assets (Q)
$272.28M
Total Debt (Q)
$42.99M
Total Liabilities (Q)
$76.45M
Book Value Per Share (Q)
$5.22
Cash Flow
Cash from Operations (TTM)
-$97.01M
Cash from Investing (TTM)
$63.41M
Cash from Financing (TTM)
-$735.00K
Net Change in Cash (TTM)
-$34.33M
Filings
Filing Date
Tuesday, August 12, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 10 and 14 (est)
Price History
Loading...
Beta
--
7-Day Total Return
-13.21%
30-Day Total Return
58.79%
60-Day Total Return
28.44%
90-Day Total Return
95.27%
Year to Date Total Return
-23.75%
1-Year Total Return
44.50%
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Apr 04, 2025 - $1.23
52-week High
Dec 10, 2024 - $4.92
Valuation
Market Cap
$108.47M - Micro Cap
Enterprise Value
-$53.53M
Price/Sales (TTM)
3.18
Price/Book (Q)
0.55
Dividends and Shares
Shares Outstanding
37.16
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
metagenomi.co
Phone Number
510 871 4880
Address
5959 Horton Street
EmeryVille, CA 94608
Country
United States
Year Founded
2016
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes... more
NASDAQ 10/24/2025 4:00PM Eastern Quotes delayed